Sign in →

Test Code FUROC UroVysion for Detection of Bladder Cancer, Urine

Useful For

Monitoring for tumor recurrence in patients with a history of urothelial carcinoma involving the bladder or upper urinary tract


Assessing patients with hematuria for urothelial carcinoma

Special Instructions

Method Name

Fluorescence In Situ Hybridization (FISH) Using DNA Probes

Reporting Name

UroVysion (R) for Bladder Cancer

Specimen Type


Necessary Information

1. Specimen source is required on request form (ie voided, catheterized, bladder washing).

2. Provide fixative, source, reason for referral (Evaluate for urothelial carcinoma or Hematuria.) and status of diagnosis (known previous diagnosis or suspected/unknown).

Specimen Required

Specimen Type: Urine

Sources: Voided urine, catheterized urine, bladder washings, stoma collections, ureteral brushings or washings, and renal pelvic brushings or washings

Supplies: FISH for Urothelial Carcinoma Urine Collection Kit (T509)


Preferred: FISH for Urothelial Carcinoma in Urocyte Urine Collection Kit (T509)

Acceptable: 70% ethanol, PreservCyt, CytoLyt

Specimen Volume: 30 mL

Collection Instructions:

1. Follow instructions included with Urocyte Urine Collection Kit.

2. If kit is not used, submit a random urine specimen with an equal volume of 70% ethanol, PreservCyt, or CytoLyt.

Specimen Minimum Volume

30 mL is recommended, however, will not reject if <30 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Refrigerated (preferred)

Reject Due To

No specimen should be rejected.

Clinical Information

Cystoscopy and urine cytology have been the primary methods for detecting urothelial carcinoma (UC). Unfortunately urine cytology has relatively poor sensitivity for the detection of recurrent UC. This is problematic because patients who have undetected recurrent tumors may have tumor progression that places them at increased risk of developing metastatic UC.


The UroVysion assay is a FISH assay for the detection of recurrent UC. The UroVysion probe set contains probes to the centromeres of chromosomes 3, 7, and 17, and a locus-specific probe to the 9p21 band (site of the P16 tumor suppressor gene). The UroVysion assay detects cells with chromosomal abnormalities that are consistent with a diagnosis of UC. Studies have shown that the assay has higher sensitivity than urine cytology but similar specificity for the detection of recurrent UC. The UroVysion assay also demonstrates higher specificity than the BTA-stat assay for recurrent UC.

Reference Values

An interpretive report will be provided.

Day(s) and Time(s) Performed

Monday through Friday; 6 a.m.-8 p.m.

Saturday; 10 a.m.-6:30 p.m.

Sunday; 1 p.m.-9:30 p.m.

Analytic Time

4 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
FUROC UroVysion (R) for Bladder Cancer 82251-0


Result ID Test Result Name Result LOINC Value
54674 Result Summary 50397-9
54675 Result 82251-0
54676 Interpretation 69047-9
54677 Reason for Referral 42349-1
54678 Specimen 31208-2
54679 Source 31208-2
54680 Released By 18771-6

NY State Approved



1. Pathology/Cytology Information (T707) in Special Instructions

2. If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.